Skip to content

Royalty Pharma

US · RPRX #759 by market cap Listed 2020
68.45 +0.73 +1.08%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 68.17 +0.66%
After-hours 67.91 -0.79%
Overnight 68.19 +0.69%
69.7752.5768.452026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on RPRX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +47.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall B+
ValuationGrowthProfitMomentumHealthAnalyst
Valuation D-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 44.7x Better than 11%
Forward P/E 40.7x Better than 10%
Price / Sales 11.6x Better than 9%
P/E vs own 5-yr range 84th pctl Better than 22%
Growth B+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 2.1% Better than 35%
Net income CAGR (3Y) 162.1% Better than 98%
Free cash flow CAGR (3Y) 5.1% Better than 46%
Profitability A-

How much profit the business keeps from each dollar of sales and capital.

Operating margin 65.6% Better than 99%
Net margin 32.4% Better than 92%
Return on equity 11.5% Better than 57%
Return on invested capital 7.0% Better than 55%
Momentum A+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 12.0% Better than 92%
6-month return 26.5% Better than 88%
12-month return (ex latest month) 66.3% Better than 89%
Distance below 52-week high 2.4% Better than 98%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.4x Better than 64%
Debt to assets 45.6% Better than 19%
Interest coverage 5.3x Better than 58%
Free cash flow / net income 323.0% Better than 87%
Analyst View C+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 6.2% Better than 9%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -1.24%
1M +10.34%
3M +13.38%
6M +29.97%
YTD +80.20%
1Y +81.37%
3Y +173.30%
5Y +85.01%

Key statistics

Price & volume

Prev close
67.72
Open
68.17
Day range
67.95 - 68.83
Avg price
68.41
Volume
3.53M
Turnover
241.62M
Amplitude
1.30%
52-week range
36.68 - 70.13

Valuation

P/E
38.46
P/E (TTM)
44.74
P/B
4.46
EPS
1.78
Net profit
792.57M
Net assets
6.84B

Share structure

Market cap
30.48B
Float cap
28.44B
Shares out
445.27M
Float shares
415.52M

Dividend & listing

Dividend (TTM)
0.93
Listing date
2020-06-16
52-week range 95% of range
36.68 70.13

2.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-54.18M net over the window

Short interest

Shares short
13.08M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Royalty Pharma (RPRX)?

Royalty Pharma last traded at 68.45. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Royalty Pharma's market cap?

About 30.48B.

What is the P/E ratio of Royalty Pharma?

The trailing twelve-month P/E is 44.74, above its own 5-year average of 42.10 — toward the top of its historical range (83.51% percentile). See the Valuation tab for the full history.

Does Royalty Pharma pay a dividend?

Yes. The trailing dividend yield is 1.35%. The 2025 payout was up 4.8% from 2024. See the Dividends tab for the full payment history.

Is Royalty Pharma a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 72.67, which implies 6.2% upside from the current price. This is not investment advice.

What is Royalty Pharma's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Royalty Pharma a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:28 · For reference only, not investment advice and not tailored to your situation.

Royalty Pharma discussion 0 comments

Add a comment